Introduction {#Sec1}
============

Since the outbreak of the 2019 novel coronavirus (named 2019-nCoV by the World Health Organization) (Wu et al. [@CR26]), also named coronavirus disease 2019 (Covid-19) or SARS-CoV-2, the disease has spread to a global pandemic. The effects of this pandemic not only on public health and health care institutions, but also on nearly every aspect of social life and worldwide economy is unprecedented in postmodern history. The speed of its distribution, since the discovery on 30 December 2019 of a new virus in the bronchioalveolar lavage (BAL) (samples taken from the lung content) of a patient at Wuhan Jinyingtan Hospital (Hubei province, China) (WHO [@CR25]) until today---which is less than 3 months---has caused a shockwave in a number of severely struck countries. Unfortunately, it may have caused a lot of confusion in the public media too. Especially the high rate of fatalities, following the incidence of acute respiratory distress syndrome (ARDS) has raised the stakes of national health authorities up to the highest levels of vigilance and promulgation of the most extreme measures.

This paper aims at summarizing the information already available concerning the etiology, genomic background and epidemiology of COVID-19. In particular, similarities and differences observed in related species of the Coronaviridae (order Nidovirales), especially of the genus *Betacoronavirus*, and most predominantly the *SARS*-*related Rhinolophus bat coronavirus* (SARSr BaCoV HKU3) and *SARS*-*related human coronavirus* (SARS CoV Urbani) (International Committee on Taxonomy of Viruses [@CR13]) are helpful to understand the pathogenicity of this new coronavirus. The COVID-19 pandemic strongly recalls characteristics of the severe acute respiratory syndrome (SARS) pandemic of 2002--2003, and therefore has been called SARS-CoV-2 in many studies too. However, especially the differences between SARS, Influenza and COVID-19 are crucial to comprehend the divergent epidemiology and pathogenicity of these diseases (Wu et al. [@CR26]; Weiss and Leibowitz [@CR24]). Moreover, the etiology of pneumonia in these diseases and important correlations between SARS-related and COVID-19-related ARDS are summarized in Sect. [3](#Sec3){ref-type="sec"}.

From the early phases of the outbreak of COVID-19 it has been noted that people above the age of 60 years belong to a high risk group for developing fatal organ failure, especially due to lung damage. In some countries, the age level for high risk patients was set at 70 (e.g. in the United Kingdom). Whereas the overall Case Fatality Ratio (CFR) from a large Chinese study group was determined as 2.3% (The Novel Pneumonia Emergency Response Epidemiology Team [@CR21]), it was clear that higher CFR's were found in elder people. An alternative to expressing the fatality of the coronavirus diseases in terms of CFR is to calculate the *standard expected years of life lost* (SEYLL index) (Salamatbakhsh et al. [@CR19]). Important co-morbidities were ascribed to hypertension (CFR 6.0%), diabetes (CFR 7.3%), cardiovascular disease (CFR 10.5%) and age above 70 (CFR 10.2%) (Novel Pneumonia Emergency Response Epidemiology Team [@CR21]). Due to the association of at least two of these co-morbidities with the widely prescribed use of ACE-inhibitors---for instance used for blocking the angiotensin-receptor (ATR) in order to lower blood pressure (for hypertensive and cardiac patients altogether)-, the risks of developing ARDS in these patient groups should be considered with highest priority. So far, only animal experiments have documented that ACE-inhibitors can significantly increase mRNA expression of cardiac ACE2 (Ferrario et al. [@CR7]), but some already caution for using ACE inhibitors as potential risk factor (Sommerstein [@CR20]). It is concluded that all possible public health protection measures for these category of patients, in addition to the infectivity measures against spreading the COVID-19 virus among all age groups, need our highest priority attention.

Etiology and Genomic Background of COVID-19, SARS and MERS {#Sec2}
==========================================================

Initial genomic analysis has shown a close evolutionary association with the SARS-like bat coronaviruses (Wu et al. [@CR26]). This relationship is confirmed by 96% genomic similarity of the full-length genome sequence of the COVID-19 virus with a SARS-like coronavirus strain derived from *Rhinolophus* bat (BatCoV RaTG13) (WHO [@CR25]). Only recently it was shown that genomic recombination from the Chinese Greater Horseshoe bat *(R. sinicus)* was at the onset of the SARS outbreak (Lau et al. [@CR14]). Similar to the SARS outbreak of 2002--2003, the viral tropism towards the respiratory system is striking, but the timing of the highly infective phases of the disease are also very different from SARS. The very high human-to-human infectivity of COVID-19 and resulting pneumonia, has been documented following close surveillance of pneumonia in a family cluster, early during the Wuhan epidemic (Chan et al. [@CR5]).

In the etiology of late phase severe lung damage, an important role is played by the angiotensin converting enzyme 2 (ACE2) as well as by lymphocytic inflammatory responses (Weiss and Leibowitz [@CR24]). It has been known for a while that ACE2 is involved in acute lung injury in mice (Imai et al. [@CR12]) and that ACE2 is a receptor of the spike (S) glycoprotein of both Mouse Hepatitis Virus (MHV-2)---also a *Betacoronavirus* causing virulent pneumonia---and SARS-related CoV (Weiss and Leibowitz [@CR24]). The importance of this ACE2 receptor for cellular infectivity of the virus is strengthened by the finding that no amino acid substitutions have been found in the corresponding genome region of 2019-nCoV, compared with the receptor-binding motifs that directly interact with human ACE2 as recognized in the SARS-CoV genome (Wu et al. [@CR26]). Meanwhile, it has been demonstrated that 2019-nCoV uses the same ACE2 receptor---similar to the SARS-coronavirus receptor ACE2---and the cellular protease TMPRSS2 for entry into target cells (Hoffmann et al. [@CR10]). Moreover, ACE2 expression is very predominant in both Type 1 and Type 2 alveolar pneumocytes of the human lung, as well as in the intestine and kidney (Turner [@CR23]).

In contrast to the former examples of *Betacoronaviruses* (MHV-2, SARSrCoV and 2019 nCoV), in the middle east respiratory syndrome (MERS) (Toosy and O'Sullivan [@CR22]) a different cell entry of the MERS-related coronavirus (MERS-CoV) was discovered: namely the cellular receptor dipeptidyl peptidase 4 (DPP4, also known as CD26) (Raj et al. [@CR17]). The epidemiology of MERS is quite different from that seen in SARS (Toosy and O'Sullivan [@CR22]) and also from COVID-19. The receptor for viral entry, DPP4 (CD26) is for instance expressed in cells of the monocyte-macrophage lineage. Moreover, DPP4 is expressed on epithelial and endothelial cells of most human organ tissues (in ex vivo studies using human culture lines), suggesting this may account for the multisystem clinical spectrum of MERS-CoV infection (Turner [@CR23]). Although also MERS has been associated with a coronavirus lineage present in Vesper bats (in particular *Pipistrellus hesperidus*, Vespertilionidae) in Uganda, there was a high divergence of the S protein nucleotide sequence compared with a MERS-CoV S protein sequence (Anthony et al. [@CR3]). This suggests that the viruses are different and-although bats are the plausible evolutionary source of MERS CoV---another intermediate mammalian reservoir species is probably responsible for transmission of MERS to humans (Turner [@CR23]). This appears to be the wild population of Dromedary camels in the Arabian Peninsula, as well as in North and East Africa. It is suggested that the limited geographic distribution of MERS-CoV is related to the distribution of these dromedary camels (DCs). When DCs are infected, MERS-CoV causes only a mild, transient upper respiratory tract disease (Turner [@CR23]).

Genomic analysis of the 2019-nCoV and closely related coronaviruses already has revealed a number of important differences (Wu et al. [@CR26]). In order to understand the impact of these differences on pathogenicity and epidemiology, it is important to have access to the genomic structure of the virus RNA (See Fig. [1](#Fig1){ref-type="fig"}a) (Wu et al. [@CR26]; International Committee on Taxonomy of Viruses [@CR13]). First a distinction is made in genes coding for structural (glyco)proteins (Fig. [2](#Fig2){ref-type="fig"}) forming a common backbone in many groups of the Nidovirales: these include the spike glycoprotein (S), the membrane glycoprotein (M), the envelope protein (E), the nucleocapsid protein (N) and the hemagglutinin-esterase glycoprotein (HE). However, the latter HE is absent from both SARSr human CoV, and from SARSr bat CoV as well as from 2019-nCoV (Wu et al. [@CR26]) (Fig. [1](#Fig1){ref-type="fig"}b). In other members of the *Betacoronavirus* genus, like in *Human coronavirus* HKU1 (International Committee on Taxonomy of Viruses [@CR13]), HE is important for reversible attachment of virions to O-acetylated sialic acids, by acting both as a lectin and as a sialate-*O*-acetylesterase. This however is not the case in neither SARS nor 2019-nCoV. Also for the relatively innocuous *Human coronavirus* OC43 (causing only a mild cold), it is suggested that 9-*O*-acetylated sialic acid is the primary attachment factor, and not the ACE2 receptor (International Committee on Taxonomy of Viruses [@CR13]). Sialic acid plays an important role in cellular recognition and ganglioside metabolism, and is found as a common modification at the outside of glycoproteins. For instance, the 9-*O*-acetylation of these sialoglycans has been shown to play a role in host--pathogen interactions with functional implications in the immune system (like impaired binding of influenza A and B, but at the same time creating a receptor for influenza C) (Baumann et al. [@CR4]).Fig. 1**a** Schematic diagram of genome organization and the encoded proteins for 2019-nCoV (based on genome of Wuhan/IVDC-HB-01/2019 virus) (© 2020 Elsevier Inc.) (adapted from Wu et al. [@CR26]). *pp1a*, *pp1ab* polyprotein 1a, resp 1 ab, *nsp* non-structural protein. See main text for clarification of used symbols. **b** Schematic genome organization in the A- and B-group, of genus *Betacoronavirus* (© 2012 International Committee on Taxonomy of Viruses; publ. Elsevier Inc.) The figure shows the genomes of a number of representative species (only the 3′-terminal genomic regions downstream of ORF1b are shown. Mark the absence of the HE region (coding for hemagglutinin esterase enzyme) in SARS related bat and human CoV (see Fig. [2](#Fig2){ref-type="fig"} for enzyme codes and also main text for abbreviations of virus names)Fig. 2Schematic representation of a lineage A betacoronavirus virion (© 2012 International Committee on Taxonomy of Viruses; publ. Elsevier Inc.) S: the spike (glyco) protein (responsible for binding to the host cell receptor ACE2 in SARS CoV and 2019-nCoV); *HE*: Hemagglutinin Esterase (not expressed in B lineage, see also Fig. [1](#Fig1){ref-type="fig"}b). *M* membrane glycoprotein, *N* nucleocapsid protein, *E* envelope protein. Both S and HE proteins are heavily glycosylated, M contains a small number of glycans, concerning the species. Moreover, the S and E proteins are palmitoylated, providing them their hydrophobic features

Beside the structural (glyco)proteins, an important number of non-structural proteins are generated from the virus genome, with a variety of functions like degradation of host mRNAs, polyprotein processing and association with replicase/transcriptase complexes (International Committee on Taxonomy of Viruses [@CR13]). In the so-called *open reading frames* (ORF 1ab and ORF 1a), both situated at the 5′-terminus of the genome of 2019-nCoV---as well as in most *Betacoronavirus* genomes-, a number of *non*-*structural proteins* (nsps) are encoded (International Committee on Taxonomy of Viruses [@CR13]) (Fig. [1](#Fig1){ref-type="fig"}a). In 2019-nCoV the first ORF represents 67% of the entire genome, being transcribed into so-called polyproteins that are further processed into 16 nsps (Wu et al. [@CR26]). Beside a number of differences in the nsps encoding ORF, also in the eight so-called accessory proteins that are encoded in ORF's near the 3′ end of the genome, important differences have been noted between 2019-nCoV and SARS-like coronaviruses (Wu et al. [@CR26]). However, a lot of research and time will be needed to understand how these differences may affect the pathogenicity and epidemiology of 2019-nCoV: this precious time, unfortunately, might not be available for a large proportion of our population.

Risk Factors for Acute Respiratory Distress Syndrome (ARDS) {#Sec3}
===========================================================

Because the 2019-nCoV also uses the ACE2 receptor for entry in the host-like the SARS-related CoV---and because the very dangerous reactions this interaction may cause in the human lung, a lot of information is already present in medical publications.

The pharmacology of the angiotensin converting enzyme 2 (ACE2), its physiological role and relationship with *acute respiratory distress syndrome* (ARDS), already have been studied extensively (Imai et al. [@CR12]). ARDS is known as a very severe, life-threatening form of *acute lung injury* (ALI). Many pathogenic conditions have been found to trigger ARDS, not only SARS and COVID-19, but also pathogens like Anthrax, Spanish flu virus and H5N1 avian influenza virus (Rubenfeld et al. [@CR18]). However, the association of binding of the coronavirus spike glycoprotein (S) with ACE2, and subsequent catalytic cleavage in the endosome (at low pH, involving cathepsin L and a second leu-peptin-sensitive-like cleavage in the case of SARS-CoV) (Weiss and Leibowitz [@CR24]), so far is characteristic for only a few members of the *Betacoronavirus* genus (see also Sect. [2](#Sec2){ref-type="sec"}).

The pathogenic effects of coronavirus entry using the ACE2 receptor in for instance lung epithelial cells appear to follow two paths: on the one hand, spike-receptor interaction causes downregulation and abolishment of the protective function of ACE2, resulting in local enhancement of angiotensin II production and unrestricted stimulation of the angiotensin receptor (AT~1~R) (Imai et al. [@CR12]) (Fig. [3](#Fig3){ref-type="fig"}). On the other hand, the binding of ACE2 to SARS-CoV spike glycoprotein induces so-called syncytia-formation and transformation into large multinucleated cells, as observed in clinical SARS infections (Imai et al. [@CR12]) and also in post mortem samples taken from a 50-year old male patient from Wuhan (WHO [@CR25]). It was already suggested that severe lung damage, especially in the late phase of SARS, was largely 'immunopathological in nature' (Weiss and Leibowitz [@CR24]). In early phase fatal lung disease, histological examination showed hyaline membrane formation (indicative of ARDS) (World Health Organization [@CR25]) and loss of lung epithelial cells (or pneumocytes), resulting alveolar damage and mixed cellular infiltrates of lymphocytes (Weiss and Leibowitz [@CR24]). Often also multinucleated giant cells, carrying markers for both macrophages and pneumocytes were present (Weiss and Leibowitz [@CR24]), indicating the involvement of macrophage scavenging. Also in 2019-nCoV infections, these histological features were observed in post mortem specimen from lung (apart from the demonstration of lineage markers) (World Health Organization [@CR25]). In the late phase of SARS (phase III, 10--15 days after the onset of illness), also type II pneumocyte hyperplasia, squamous metaplasia and bronchiolitis obliterans were found in histological examination. These features are consistent with the late, irreversible obstruction of the bronchioles (Weiss and Leibowitz [@CR24]). The worsening of clinical progression, simultaneously with declining viral loads and markedly elevated cytokine levels, the so-called cytokine-storm (during SARS phase III, but also seen in COVID-19), corroborate the conclusion that these late pathological effects are the result of a fatal overreaction of the immune system (Weiss and Leibowitz [@CR24]) (see below).Fig. 3Schematic diagram representing the role of the renin-angiotensin system in acute lung failure and proposed SARS-CoV action during infection (© 2008 The Physiological Society) (adapted from Imai et al. [@CR12])."In acute lung injury, such as acid aspiration, pneumonia or scepsis, the generation of Ang II from Ang I is enhanced by ACE, and Ang II induces acute lung failure through stimulation of AT~1~R while ACE2 and AT2R negatively regulate this pathway and protect from acute lung failure. In contrast, SARS-CoV infection is mediated through binding of the SARS Spike Protein to ACE2 (...) and downregulates the protective molecule ACE2, thus leading to severe lung injury and acute lung failure" (cited from Imai et al. [@CR12]) (A possible, alternative route via L-SIGN, i.e. the liver/lymph node-specific intercellular adhesion molecule-3-grabbing nonintegrin, may result in a similar clinical outcome)

Similarly, in a large Chinese study, also other groups with impaired lung functioning, like patients with *chronic obstructive pulmonary disease* (COPD), have shown to constitute an important risk with high co-morbidity rate when infected with this new coronavirus (Guan et al. [@CR8]). To these potential risk groups, also patients with *fibrotic lung* developments following several (auto) immune disorders (like rheumatoid arthritis, systemic lupus erythematosus \[SLE\], scleroderma, etcetera) and other etiologies causing impaired lung functioning, may be added. The importance of resident lung macrophages in keeping a tolerant immune state of the lungs, in order to strongly inhibit local T cell responses, has been noted for a considerable time (Holt [@CR11]). During inflammation, a 'protective' immune reaction is raised, involving T cell reactions directed to the lungs (Holt [@CR11]). However, obviously, insufficient knowledge is available enabling us to link the activated characteristics of a patient's immune system and the risk of developing ARDS following infection with 2019 nCoV. Similar to the risk of developing allergic disorders, too little information is yet applicable on the importance of a T-helper-2-type responsiveness (tolerogenic) versus a T-helper-1-type responsiveness (inflammatory reaction) in the immune reactions to these viral infections (Allaerts and Chang [@CR1]).

After some initial optimism, suggesting the potential usefulness of ACE-inhibitors and/or AT~1~R inhibitors to build protection against severe lung damage (Weiss and Leibowitz [@CR24]), recent experimental findings have raised some doubts (Ferrario et al. [@CR7]) or cautioned against its use as prophylactic medication (Sommerstein [@CR20]). Given the increased vulnerability of patients with age and the widespread use of ACE-inhibitors, more research into the epidemiological relation between the use of ACE-inhibitors and 2019-nCoV-related ARDS is needed. To our opinion, this should become prioritized in global public health research related to COVID-19.

During the SARS pandemic, it appeared that the SARS-CoV spike protein (S) was a primary factor in determining the virulence of the attack, "beyond its role in viral attachment and cell entry"(Weiss and Leibowitz [@CR24]). Experiments in vitro using mouse heart cells, moreover, have shown the downregulation of ACE2, following viral inflammation and viral replication in the myocardium cells (Weiss and Leibowitz [@CR24]). This suggests that also cardiac infection could contribute to SARS mortality (Oudit et al. [@CR16]). Similarly, ACE-inhibition may influence renal function and interstitial renal damage following SARS infection (Hamming [@CR9]). Also during the COVID-19 epidemic in China, chronic kidney diseases also have constituted a high co-morbidity factor comparable to the comorbidity associated with diabetes, following the highest comorbidity associated with hypertension (Guan et al. [@CR8]). The combination of lung, cardiac and/or renal failure creates a fatal mixture at intensive care hospitals, when SARS patients often were already in their third week of illness and symptoms of viral infection were declining (Weiss and Leibowitz [@CR24]).

Epidemiological Lessons from Other Coronaviridae and New Viral Diseases {#Sec4}
=======================================================================

One of the cardinal questions related to this new burden of coronavirus-related diseases is how humanity will deal with it, apart from the questions of how recurrent pandemics would influence the world economy, the demography and migration patterns and finally also the world climate system. But none of these questions may find an answer without acknowledging the moral connotations involved in these questions. I choose not to go in that direction and rather confine what we may learn from the present and past pandemics/epidemics.

In the case of MERS, yearly recurrent episodes of epidemics were registered since the first outbreak in 2012. Also here the CFR was very high, namely 36% (690 fatalities of a total of 1936 WHO-confirmed cases) (Toosy and O'Sullivan [@CR22]). An outspoken difference between MERS and 2019-nCoV is the limited distribution of the MERS epidemic, predominantly occurring in the Arabic peninsula, with one significant exception: this was the MERS outbreak in the Republic of (South) Korea in May--July 2015 (Toosy and O'Sullivan [@CR22]). Nevertheless, MERS also caused victims in a large number of countries outside the region (Toosy and O'Sullivan [@CR22]). These data suggested that the MERS-related coronavirus was less infective, which may or not be attributable to a different entry of the virus (see Sect. [2](#Sec2){ref-type="sec"}).

Although the following results are still premature, recent studies at Erasmus MC in Rotterdam suggest that the increased infectivity of the 2019 nCoV, for instance compared with the SARS pandemic, may result from a much higher rate of virus shedding from the upper respiratory organs, especially from the nasal epithelium. Nearly 3 months after the outbreak of this new pandemic, it is way too early to draw firm conclusions from these observations. Also it is rather early to draw conclusions about a possible seasonal influence of the new virus. A possible seasonality dependence however has been suggested for other coronaviruses, e.g. causing the seasonal cold (like the *Human coronavirus* OC43), and the viruses causing influenza and other viral diseases (Martinez [@CR15]). In a commentary paper, Cohen ([@CR6]) suggests that cold and dry air conditions, like in the ski-resorts in Northern Italy and other alpine regions, may have constituted ideal conditions for human-to-human infectivity (Cohen [@CR6]). However, suggestions of the ideal humidity conditions in the air and airways, are very speculative and may constitute a dangerously biased surmise of protection. If physical parameters would offer such a degree of protection, by lowering the infectivity rate, this could only become noted after several seasons of the pandemic have passed.

Also the idea of acquiring immunity after recovering from the disease is a hopeful prospect, but a dangerously flawed idea for the risk groups with high CFR's (see Sect. [1](#Sec1){ref-type="sec"}). Without detailed knowledge of the etiology of the late immune responses causing vital organ failure and high numbers of fatalities, classical models do not answer these unfamiliar diseases (Allaerts [@CR2]). Technically, models based on incorporating acquired-immunity during the spreading of an epidemic, may become flawed in the case of SARS and COVID-19, because of a misinterpretation of the totality of immune reactions involved (see Sect. [3](#Sec3){ref-type="sec"}). Whether or not alternative models based on different mathematical distributions (Allaerts [@CR2]) are better suited, is too early to decide at this stage of the pandemic. Also the WHO-report (World Health Organization [@CR25]) cautions, because, so far it is unknown how immunity against 2019-nCoV will become built up by the recovered patients. Besides, the potentially high risk of a frequently mutating virus-pool---changing its antigenic properties in the course of the seasons ahead---may dampen our optimism, despite the worldwide efforts to raise a vaccine against this new COVID-19. For comparison, the MERS epidemic resulted from a mutation in the pool of bat coronaviruses around 2012 (Toosy and O'Sullivan [@CR22]), whereas also the new bat related coronaviruses SARS-CoV and SARS-CoV-2 appeared in a time span of only two decades (2002--2019).

Summary of Questions for Further Research {#Sec5}
=========================================

To summarize the present paper, a few highlights will be listed. However, this paper is not about how to organize a state of medical emergency, and neither about how to organize the production of masks and other protective clothing, nor about providing sufficient beds and electric fans for breathing machines. It is an attempt to summarize the present state-of-knowledge and in particular to understand the missing gaps in our knowledge of this pandemic. It appears that understanding this pandemic requires not only the knowledge of virologists, epidemiologists, intensive care physicians, immunologists and specialists of the interactions between the viral genomes and our human biochemistry, but the knowledge of all of them, together!

The following shortlist represents key areas where our limited knowledge should merit further scientific research: (1) correlation of previous medication use (especially ACE inhibitors) and disease progression in the groups of patients associated with high-comorbidity risks; (2) characterizing the immunological profile (multiple immunophenotyping, but also assessment of cytokine production profiles especially during early phases of the disease, prior to acute lung injury) of patients at risk for developing *acute respiratory distress syndrome* (ARDS); (3) influence of genomic differences between coronaviruses related to both structural (glyco)proteins and non-structural proteins, on the epidemiology and pathogenicity of these viruses, in particular on the infectivity, the speed of virus production and shedding and the biochemical entry routes with the host cells. Also the immunological reactions to these viral-host interactions by the host immune system are of primary importance. The latter route may also become very instructive for directing vaccine development to this 2019-nCoV.

Up to date, a lot of knowledge has been acquired about the etiology and severity of this pandemic, reflected by the CFR ratios, the age-distribution and comorbidities associated with its victims. Hopefully, science will come up with answers to questions regarding the underlying mechanisms too, in order to better protect public health.
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